In conclusion, for the first time, this present study shows preliminary indication that inherited variations promoted by MSH3 rs26279, EXO1 rs1047840 and EXO1 rs9350, involved in DNA MMR pathway, may alter side effects and response CDDP and RT in HNSCC patients. The gene discussed is MSH3; the disease is head and neck squamous cell carcinoma.